Gilder Gagnon Howe & CO LLC Tarsus Pharmaceuticals, Inc. Transaction History
Gilder Gagnon Howe & CO LLC
- $8.39 Billion
- Q2 2025
A detailed history of Gilder Gagnon Howe & CO LLC transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Gilder Gagnon Howe & CO LLC holds 77,164 shares of TARS stock, worth $3.96 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
77,164
Previous 416,811
81.49%
Holding current value
$3.96 Million
Previous $21.4 Million
85.4%
% of portfolio
0.04%
Previous 0.3%
Shares
4 transactions
Others Institutions Holding TARS
# of Institutions
214Shares Held
46.3MCall Options Held
7.8KPut Options Held
0-
Black Rock Inc. New York, NY3.27MShares$168 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY3.11MShares$160 Million1.94% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.98MShares$153 Million5.63% of portfolio
-
Jennison Associates LLC2.47MShares$127 Million0.06% of portfolio
-
Tang Capital Management LLC San Diego, CA2.45MShares$126 Million5.96% of portfolio
About Tarsus Pharmaceuticals, Inc.
- Ticker TARS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,658,500
- Market Cap $1.37B
- Description
- Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...